Andrew T Trout, Thomas P Boike, Anca M Avram, Parul Barry, Simin Dadparvar, Sai Duriseti, Robert R Flavell, Frederick D Grant, Neha Kwatra, Hollie A Lai, Marguerite T Parisi, Sue S Yom, Mark Tulchinsky, Munir V Ghesani, Rathan M Subramaniam, Terry L Levin, William Small, Naomi R Schechter
{"title":"I-131碘化钠治疗良恶性甲状腺疾病的ACR-ACNM-ARS-SNMMI-SPR实践参数","authors":"Andrew T Trout, Thomas P Boike, Anca M Avram, Parul Barry, Simin Dadparvar, Sai Duriseti, Robert R Flavell, Frederick D Grant, Neha Kwatra, Hollie A Lai, Marguerite T Parisi, Sue S Yom, Mark Tulchinsky, Munir V Ghesani, Rathan M Subramaniam, Terry L Levin, William Small, Naomi R Schechter","doi":"10.1097/COC.0000000000001239","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>This practice parameter was developed collaboratively by the American College of Radiology (ACR), the American College of Nuclear Medicine (ACNM), the American Radium Society (ARS), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), and the Society for Pediatric Radiology (SPR). This practice parameter is intended to guide appropriately trained and licensed physicians in the oral administration of I-131 sodium iodide for the treatment of benign and malignant thyroid diseases.</p><p><strong>Methods: </strong>This practice parameter was revised according to the process described under the heading The Process for Developing ACR Practice Parameters and Technical Standards on the ACR website (https://www.acr.org/Clinical-Resources/Practice-Parameters-and-Technical-Standards) by the Committee on Practice Parameters-Nuclear Medicine and Molecular Imaging of the ACR Commissions on Nuclear Medicine and Molecular Imaging, the Committee on Practice Parameters-Radiation Oncology of the ACR Commission on Radiation Oncology, the Committee on Practice Parameters-Pediatric Radiology of the ACR Commission on Pediatric Radiology in collaboration with the ACNM, the ARS, the SNMMI, and the SPR.</p><p><strong>Results: </strong>I-131 sodium iodide is used for the treatment of hyperthyroidism and differentiated thyroid cancer. The therapeutic effect of I-131 sodium iodide is achieved by the emission of ionizing radiation in the form of high-energy beta particles. I-131 sodium iodide therapy requires close cooperation and communication between the clinicians who are responsible for the clinical management of the patient and the physicians who administer radiopharmaceutical therapy. This document provides guidance regarding optimal therapy procedures, appropriate precautions, and therapy in unique situations.</p><p><strong>Conclusions: </strong>This practice parameter is designed to assist practitioners in providing appropriate radiologic care for treating benign and malignant thyroid disease with I-131 sodium iodide.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"ACR-ACNM-ARS-SNMMI-SPR Practice Parameter for Treatment of Benign and Malignant Thyroid Disease With I-131 Sodium Iodide.\",\"authors\":\"Andrew T Trout, Thomas P Boike, Anca M Avram, Parul Barry, Simin Dadparvar, Sai Duriseti, Robert R Flavell, Frederick D Grant, Neha Kwatra, Hollie A Lai, Marguerite T Parisi, Sue S Yom, Mark Tulchinsky, Munir V Ghesani, Rathan M Subramaniam, Terry L Levin, William Small, Naomi R Schechter\",\"doi\":\"10.1097/COC.0000000000001239\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>This practice parameter was developed collaboratively by the American College of Radiology (ACR), the American College of Nuclear Medicine (ACNM), the American Radium Society (ARS), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), and the Society for Pediatric Radiology (SPR). This practice parameter is intended to guide appropriately trained and licensed physicians in the oral administration of I-131 sodium iodide for the treatment of benign and malignant thyroid diseases.</p><p><strong>Methods: </strong>This practice parameter was revised according to the process described under the heading The Process for Developing ACR Practice Parameters and Technical Standards on the ACR website (https://www.acr.org/Clinical-Resources/Practice-Parameters-and-Technical-Standards) by the Committee on Practice Parameters-Nuclear Medicine and Molecular Imaging of the ACR Commissions on Nuclear Medicine and Molecular Imaging, the Committee on Practice Parameters-Radiation Oncology of the ACR Commission on Radiation Oncology, the Committee on Practice Parameters-Pediatric Radiology of the ACR Commission on Pediatric Radiology in collaboration with the ACNM, the ARS, the SNMMI, and the SPR.</p><p><strong>Results: </strong>I-131 sodium iodide is used for the treatment of hyperthyroidism and differentiated thyroid cancer. The therapeutic effect of I-131 sodium iodide is achieved by the emission of ionizing radiation in the form of high-energy beta particles. I-131 sodium iodide therapy requires close cooperation and communication between the clinicians who are responsible for the clinical management of the patient and the physicians who administer radiopharmaceutical therapy. This document provides guidance regarding optimal therapy procedures, appropriate precautions, and therapy in unique situations.</p><p><strong>Conclusions: </strong>This practice parameter is designed to assist practitioners in providing appropriate radiologic care for treating benign and malignant thyroid disease with I-131 sodium iodide.</p>\",\"PeriodicalId\":50812,\"journal\":{\"name\":\"American Journal of Clinical Oncology-Cancer Clinical Trials\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-07-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Clinical Oncology-Cancer Clinical Trials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/COC.0000000000001239\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Clinical Oncology-Cancer Clinical Trials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/COC.0000000000001239","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
ACR-ACNM-ARS-SNMMI-SPR Practice Parameter for Treatment of Benign and Malignant Thyroid Disease With I-131 Sodium Iodide.
Objectives: This practice parameter was developed collaboratively by the American College of Radiology (ACR), the American College of Nuclear Medicine (ACNM), the American Radium Society (ARS), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), and the Society for Pediatric Radiology (SPR). This practice parameter is intended to guide appropriately trained and licensed physicians in the oral administration of I-131 sodium iodide for the treatment of benign and malignant thyroid diseases.
Methods: This practice parameter was revised according to the process described under the heading The Process for Developing ACR Practice Parameters and Technical Standards on the ACR website (https://www.acr.org/Clinical-Resources/Practice-Parameters-and-Technical-Standards) by the Committee on Practice Parameters-Nuclear Medicine and Molecular Imaging of the ACR Commissions on Nuclear Medicine and Molecular Imaging, the Committee on Practice Parameters-Radiation Oncology of the ACR Commission on Radiation Oncology, the Committee on Practice Parameters-Pediatric Radiology of the ACR Commission on Pediatric Radiology in collaboration with the ACNM, the ARS, the SNMMI, and the SPR.
Results: I-131 sodium iodide is used for the treatment of hyperthyroidism and differentiated thyroid cancer. The therapeutic effect of I-131 sodium iodide is achieved by the emission of ionizing radiation in the form of high-energy beta particles. I-131 sodium iodide therapy requires close cooperation and communication between the clinicians who are responsible for the clinical management of the patient and the physicians who administer radiopharmaceutical therapy. This document provides guidance regarding optimal therapy procedures, appropriate precautions, and therapy in unique situations.
Conclusions: This practice parameter is designed to assist practitioners in providing appropriate radiologic care for treating benign and malignant thyroid disease with I-131 sodium iodide.
期刊介绍：
American Journal of Clinical Oncology is a multidisciplinary journal for cancer surgeons, radiation oncologists, medical oncologists, GYN oncologists, and pediatric oncologists.
The emphasis of AJCO is on combined modality multidisciplinary loco-regional management of cancer. The journal also gives emphasis to translational research, outcome studies, and cost utility analyses, and includes opinion pieces and review articles.
The editorial board includes a large number of distinguished surgeons, radiation oncologists, medical oncologists, GYN oncologists, pediatric oncologists, and others who are internationally recognized for expertise in their fields.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
